<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Module 8: Sepsis & Emergency Antimicrobials</title>
    <style>
        /* EXACT STYLES FROM MODULE 6 */
        body {
            font-family: 'Calibri', 'Segoe UI', sans-serif;
            line-height: 1.5;
            color: #2c3e50;
            margin: 2cm;
            background-color: #ffffff;
            counter-reset: chapter section figure table;
        }
        
        h1 {
            font-size: 28pt;
            font-weight: bold;
            color: #1a5276;
            text-align: center;
            border-bottom: 3px double #3498db;
            padding-bottom: 10px;
            margin-bottom: 30px;
        }
        
        h2 {
            font-size: 18pt;
            font-weight: bold;
            color: #ffffff;
            background-color: #2980b9;
            padding: 10px 15px;
            border-radius: 5px;
            margin-top: 30px;
            page-break-after: avoid;
        }
        
        h3 {
            font-size: 14pt;
            font-weight: bold;
            color: #154360;
            margin-top: 20px;
            margin-bottom: 10px;
            page-break-after: avoid;
        }
        
        h4 {
            font-size: 12.5pt;
            font-weight: bold;
            color: #21618c;
            margin-top: 15px;
            margin-bottom: 8px;
        }
        
        .module-title {
            font-size: 20pt;
            font-weight: bold;
            color: #21618c;
            margin-top: 40px;
            border-left: 6px solid #3498db;
            padding-left: 15px;
        }
        
        .chapter-number {
            background-color: #3498db;
            color: white;
            padding: 5px 12px;
            border-radius: 50%;
            display: inline-block;
            margin-right: 10px;
            font-weight: bold;
        }
        
        /* Lists */
        ul, ol {
            padding-left: 1.5em;
            margin-bottom: 1em;
        }
        
        li {
            margin-bottom: 8px;
            font-size: 11.5pt;
        }
        
        .sub-list {
            list-style-type: lower-alpha;
            padding-left: 2.5em;
        }
        
        .drug-list {
            columns: 2;
            column-gap: 50px;
            margin-top: 15px;
        }
        
        .drug-list li {
            break-inside: avoid;
        }
        
        /* Special Boxes */
        .study-format {
            background-color: #e8f4fc;
            border: 1px solid #aed6f1;
            border-left: 6px solid #2e86c1;
            padding: 20px;
            margin-top: 30px;
            page-break-inside: avoid;
        }
        
        .clinical-pearl {
            background-color: #fff3cd;
            border: 1px solid #ffeaa7;
            border-left: 6px solid #fdcb6e;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .warning-box {
            background-color: #f8d7da;
            border: 1px solid #f5c6cb;
            border-left: 6px solid #e74c3c;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .definition-box {
            background-color: #d1ecf1;
            border: 1px solid #bee5eb;
            border-left: 6px solid #17a2b8;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        /* Tables */
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 11pt;
        }
        
        .comparison-table th {
            background-color: #2980b9;
            color: white;
            padding: 10px;
            text-align: left;
            border: 1px solid #1a5276;
        }
        
        .comparison-table td {
            padding: 10px;
            border: 1px solid #ddd;
            vertical-align: top;
        }
        
        .comparison-table tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        /* Page Layout */
        .page-break {
            page-break-before: always;
        }
        
        .footer-note {
            font-size: 9pt;
            color: #7f8c8d;
            text-align: center;
            margin-top: 30px;
            border-top: 1px solid #ecf0f1;
            padding-top: 10px;
        }
        
        /* Drug Template - EXACT MATCH */
        .drug-template {
            background-color: #f9f9f9;
            border: 1px solid #ddd;
            padding: 20px;
            margin: 25px 0;
            border-radius: 5px;
            page-break-inside: avoid;
        }
        
        .drug-template h4 {
            color: #2c3e50;
            border-bottom: 2px solid #3498db;
            padding-bottom: 5px;
            margin-top: 0;
        }
        
        .template-section {
            margin-bottom: 15px;
        }
        
        .template-label {
            font-weight: bold;
            color: #2980b9;
            display: inline-block;
            width: 180px;
        }
        
        /* Emoji Styling */
        .emoji {
            font-size: 1.2em;
        }
        
        /* Print Specific */
        @media print {
            body {
                margin: 1.5cm;
                font-size: 11pt;
            }
            
            .page-break {
                page-break-before: always;
            }
            
            .no-print {
                display: none;
            }
            
            a {
                color: black;
                text-decoration: none;
            }
        }
        
        /* Learning Objectives */
        .learning-objectives {
            background-color: #e8f6f3;
            border: 1px solid #a2d9ce;
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
        }
        
        .objective-list {
            list-style-type: none;
            padding-left: 0;
        }
        
        .objective-list li:before {
            content: "‚úì ";
            color: #27ae60;
            font-weight: bold;
            margin-right: 10px;
        }
        
        /* Module 8 Specific Colors */
        .cephalosporin-blue {
            color: #2980b9;
            font-weight: bold;
        }
        
        .penicillin-green {
            color: #27ae60;
            font-weight: bold;
        }
        
        .aminoglycoside-red {
            color: #e74c3c;
            font-weight: bold;
        }
        
        .pip-tazo-purple {
            color: #8e44ad;
            font-weight: bold;
        }
        
        .vancomycin-orange {
            color: #e67e22;
            font-weight: bold;
        }
        
        .antimalarial-teal {
            color: #17a2b8;
            font-weight: bold;
        }
        
        /* Module 8 Specific Boxes */
        .sepsis-alert {
            background-color: #f2d7d5;
            border: 2px solid #c0392b;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
            font-weight: bold;
        }
        
        .antibiotic-box {
            background-color: #d4e6f1;
            border: 2px solid #21618c;
            color: #1a5276;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .sepsis-protocol {
            background-color: #fdebd0;
            border: 2px solid #f39c12;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .antimicrobial-grid {
            background-color: #e8f8f5;
            border: 2px solid #45b39d;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }
        
        .empirical-therapy {
            background-color: #2c3e50;
            border: 2px solid #34495e;
            color: white;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }
        
        .malaria-box {
            background-color: #f4ecf7;
            border: 2px solid #8e44ad;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }
    </style>
</head>
<body>

<div class="module-title">
    <span class="emoji">üü®</span> MODULE 8: SEPSIS & EMERGENCY ANTIMICROBIALS (HIGH-YIELD)
    <div style="font-size: 12pt; font-weight: normal; font-style: italic; color: #7f8c8d;">
        (Ceftriaxone, Ampicillin, Gentamicin, Piperacillin-Tazobactam, Vancomycin, Artesunate)
    </div>
</div>

<div class="learning-objectives">
    <h3 style="color: #148f77; margin-top: 0;">üìñ Learning Objectives</h3>
    <ul class="objective-list">
        <li>Master sepsis recognition and management (Sepsis-3 criteria)</li>
        <li>Understand empiric antibiotic selection based on infection source</li>
        <li>Learn time-critical antibiotic administration in sepsis (1-hour bundle)</li>
        <li>Recognize and manage severe malaria (artesunate as first-line)</li>
        <li>Understand antibiotic pharmacokinetics/pharmacodynamics (PK/PD)</li>
        <li>Apply antimicrobial stewardship principles in emergency settings</li>
        <li>Manage antibiotic allergies and cross-reactivity</li>
        <li>Apply knowledge to common exam scenarios (meningitis, pneumonia, UTI, sepsis)</li>
    </ul>
</div>

<!-- INTRODUCTION -->
<h2><span class="chapter-number">0</span> Introduction: The Sepsis Race</h2>

<div class="warning-box">
    <strong>‚ö†Ô∏è SEPSIS IS A RACE AGAINST TIME:</strong> Every hour delay in antibiotics increases mortality by 7.6%. The "golden hour" for sepsis is REAL. Antibiotics within 1 hour of recognition. Fluids within 3 hours. Know your empiric regimens cold.
</div>

<div class="clinical-pearl">
    <strong>üß† Core Concept:</strong> Sepsis management follows four pillars:<br>
    1. <strong class="cephalosporin-blue">Early recognition</strong> (qSOFA, SOFA, clinical suspicion)<br>
    2. <strong class="cephalosporin-blue">Rapid investigation</strong> (cultures, lactate, imaging)<br>
    3. <strong class="cephalosporin-blue">Immediate treatment</strong> (antibiotics within 1 hour, fluids, source control)<br>
    4. <strong class="cephalosporin-blue">Supportive care</strong> (vasopressors, organ support, monitoring)<br>
    This module focuses on the antimicrobial interventions you MUST know.
</div>

<!-- STUDY FORMAT -->
<div class="study-format">
    <h3><span class="emoji">üìã</span> HOW WE WILL STUDY EACH DRUG (FIXED TEMPLATE)</h3>
    <p><strong>For every drug, we will follow ONE SAME FORMAT:</strong></p>
    <ol>
        <li><strong>Drug class</strong> - Pharmacological category</li>
        <li><strong>Mechanism of action</strong> - How it works at molecular level</li>
        <li><strong>Indications</strong> - Specific infection scenarios</li>
        <li><strong>Contraindications</strong> - Absolute and relative contraindications</li>
        <li><strong>Adult dose</strong> - Exact emergency dosing</li>
        <li><strong>Pediatric dose</strong> - Weight-based calculations</li>
        <li><strong>Route & preparation</strong> - How to prepare and administer safely</li>
        <li><strong>Side effects</strong> - Common, expected effects</li>
        <li><strong>Adverse effects / ADR</strong> - Serious reactions and risks</li>
        <li><strong>Drug interactions</strong> - Important combinations to avoid/watch</li>
        <li><strong>Emergency pearls</strong> - Clinical tips, exam favorites, practical wisdom</li>
    </ol>
</div>

<!-- CHAPTER 1: SEPSIS RECOGNITION & MANAGEMENT -->
<h2><span class="chapter-number">1</span> Sepsis Recognition & Management</h2>

<div class="definition-box">
    <strong>Sepsis-3 Definition:</strong> Life-threatening organ dysfunction caused by a dysregulated host response to infection. Clinical criteria: Suspected infection + SOFA score ‚â•2 or qSOFA ‚â•2 (altered mentation, RR ‚â•22, SBP ‚â§100).
</div>

<h3>1.1 Sepsis Screening (qSOFA - Quick SOFA)</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 25%;">qSOFA Component</th>
            <th>Criteria</th>
            <th>Points</th>
            <th>Clinical Significance</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Altered Mentation</strong></td>
            <td>GCS <15, confusion, drowsiness</td>
            <td>1</td>
            <td>Early sign of cerebral hypoperfusion</td>
        </tr>
        <tr>
            <td><strong>Respiratory Rate</strong></td>
            <td>‚â•22 breaths per minute</td>
            <td>1</td>
            <td>Compensatory for metabolic acidosis</td>
        </tr>
        <tr>
            <td><strong>Systolic BP</strong></td>
            <td>‚â§100 mmHg</td>
            <td>1</td>
            <td>Sign of distributive shock</td>
        </tr>
    </tbody>
</table>

<div class="sepsis-alert">
    <strong>üö® SEPSIS-6 (1-HOUR BUNDLE):</strong><br>
    1. <strong>High-flow oxygen</strong> to maintain SpO‚ÇÇ >94%<br>
    2. <strong>Blood cultures</strong> BEFORE antibiotics (x2 sets from different sites)<br>
    3. <strong>Serum lactate</strong> and venous blood gas<br>
    4. <strong>IV antibiotics</strong> within 1 HOUR of recognition<br>
    5. <strong>IV fluids</strong> 30 mL/kg for hypotension or lactate ‚â•4 mmol/L<br>
    6. <strong>Urine output measurement</strong> (catheter if needed)<br>
    <em>Time from door to antibiotics ‚â§60 minutes</em>
</div>

<h3>1.2 Source-Specific Empiric Antibiotics</h3>

<div class="empirical-therapy">
    <strong>üíä EMPIRIC ANTIBIOTICS BY SOURCE (COMMUNITY-ACQUIRED):</strong><br>
    <br>
    <strong>üî¨ MENINGITIS (Adults):</strong> Ceftriaxone 2g IV + Vancomycin 15-20 mg/kg IV + Dexamethasone<br>
    <strong>ü´Å COMMUNITY-ACQUIRED PNEUMONIA:</strong> Amoxicillin 1g IV + Doxycycline OR Ceftriaxone 2g IV + Azithromycin<br>
    <strong>üíß PYELONEPHRITIS/UTI:</strong> Ceftriaxone 1-2g IV OR Gentamicin 5-7 mg/kg IV<br>
    <strong>ü©∏ UNDIFFERENTIATED SEPSIS:</strong> Piperacillin-tazobactam 4.5g IV OR Meropenem 1g IV<br>
    <strong>ü¶† INTRA-ABDOMINAL INFECTION:</strong> Piperacillin-tazobactam 4.5g IV + Metronidazole 500mg IV<br>
    <strong>ü¶¥ OSTEOMYELITIS/SEPTIC ARTHRITIS:</strong> Flucloxacillin 2g IV + Gentamicin 5 mg/kg IV<br>
    <strong>ü©∏ NEUTROPENIC SEPSIS:</strong> Piperacillin-tazobactam 4.5g IV + Gentamicin 5-7 mg/kg IV<br>
    <strong>üå°Ô∏è SEVERE MALARIA:</strong> Artesunate 2.4 mg/kg IV at 0, 12, 24h, then daily
</div>

<!-- CHAPTER 2: DRUG 1 - CEFTRIAXONE -->
<div class="page-break"></div>
<h2><span class="chapter-number">2</span> Core Drug 1: Ceftriaxone</h2>

<div class="drug-template">
    <h4>CEFTRIAXONE - BROAD-SPECTRUM 3RD GENERATION CEPHALOSPORIN</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Third-generation cephalosporin, beta-lactam antibiotic
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds penicillin-binding proteins (PBPs) ‚Üí inhibits bacterial cell wall synthesis<br>
        ‚Ä¢ Bactericidal (concentration-dependent killing)<br>
        ‚Ä¢ Excellent CSF penetration (10-20% of serum levels) ‚Üí good for meningitis<br>
        ‚Ä¢ Time-dependent killing: Efficacy depends on time above MIC<br>
        ‚Ä¢ Long half-life (6-9 hours) ‚Üí once or twice daily dosing<br>
        ‚Ä¢ Excreted dual pathway (renal 40%, biliary 60%) ‚Üí safe in renal failure
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Community-acquired pneumonia (CAP)<br>
        ‚Ä¢ Bacterial meningitis (with vancomycin for empiric coverage)<br>
        ‚Ä¢ Complicated urinary tract infections (pyelonephritis)<br>
        ‚Ä¢ Intra-abdominal infections (with metronidazole)<br>
        ‚Ä¢ Gonorrhoea (single dose 500mg-1g IM)<br>
        ‚Ä¢ Lyme disease (neurologic, cardiac, late manifestations)<br>
        ‚Ä¢ Febrile neutropenia (with other agents)<br>
        ‚Ä¢ Surgical prophylaxis (colorectal, some orthopaedic procedures)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known severe hypersensitivity to ceftriaxone or cephalosporins<br>
        ‚Ä¢ History of anaphylaxis to penicillins (5-10% cross-reactivity)<br>
        ‚Ä¢ Hyperbilirubinemic neonates (displaces bilirubin from albumin)<br>
        ‚Ä¢ Concurrent IV calcium administration in neonates/infants (precipitation)<br>
        ‚Ä¢ Severe hepatic impairment with renal impairment (adjust dose)<br>
        ‚Ä¢ Gallbladder sludge/calculi history (ceftriaxone causes pseudolithiasis)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="cephalosporin-blue">Standard:</strong> 1-2 g IV/IM once daily<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Meningitis:</strong> 2 g IV q12h (higher dosing for CNS penetration)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Severe infections:</strong> 2 g IV q12-24h<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Gonorrhoea:</strong> 500 mg IM single dose + azithromycin 1g PO<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Surgical prophylaxis:</strong> 1-2 g IV single dose 30-60 min before incision<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Max daily dose:</strong> 4 g (rarely needed, usually 2-3 g)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="cephalosporin-blue">Neonates (0-28 days):</strong> 50 mg/kg IV once daily<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Infants/children:</strong> 50-75 mg/kg IV once daily (max 2 g)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Meningitis:</strong> 100 mg/kg IV loading, then 50-75 mg/kg q12h (max 4 g/day)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Acute otitis media:</strong> 50 mg/kg IM single dose (max 1 g)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Avoid concurrent calcium</strong> in neonates/infants (risk of precipitation)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="cephalosporin-blue">Routes:</strong> IV (preferred), IM (painful, add lidocaine)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Preparation:</strong> 250 mg, 500 mg, 1 g, 2 g vials (powder)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">IV reconstitution:</strong> Add 10 mL sterile water per 1 g = 100 mg/mL<br>
        ‚Ä¢ <strong class="cephalosporin-blue">IV infusion:</strong> Further dilute in 50-100 mL NS or D5W, infuse over 30 min<br>
        ‚Ä¢ <strong class="cephalosporin-blue">IM preparation:</strong> Add 1% lidocaine (without adrenaline) to reduce pain<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Compatibility:</strong> NOT with calcium-containing solutions, aminoglycosides (separate lines)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Diarrhea (3-10%, less than other broad-spectrum antibiotics)<br>
        ‚Ä¢ Injection site reactions (pain, phlebitis)<br>
        ‚Ä¢ Rash (1-2%, usually maculopapular)<br>
        ‚Ä¢ Elevated LFTs (transient, benign)<br>
        ‚Ä¢ Eosinophilia<br>
        ‚Ä¢ Headache, dizziness
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Anaphylaxis (rare: 0.01-0.1%)<br>
        ‚Ä¢ Clostridioides difficile infection (antibiotic-associated colitis)<br>
        ‚Ä¢ Biliary pseudolithiasis (sludge in gallbladder, usually reversible)<br>
        ‚Ä¢ Hemolytic anemia (immune-mediated, rare)<br>
        ‚Ä¢ Neutropenia, thrombocytopenia (rare, reversible)<br>
        ‚Ä¢ Nephrolithiasis (rare, from calcium-ceftriaxone precipitates)<br>
        ‚Ä¢ Seizures (high doses in renal failure)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="cephalosporin-blue">Warfarin:</strong> Increased INR (suppresses vitamin K-producing gut flora)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Calcium-containing solutions:</strong> Precipitation risk (do NOT mix or infuse concurrently)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Aminoglycosides:</strong> Synergistic but physically incompatible (separate lines)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Probenecid:</strong> Increases ceftriaxone levels (not usually co-administered)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Oral contraceptives:</strong> Reduced efficacy (theoretical, use backup)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Live vaccines:</strong> Reduced immune response (typhoid, cholera)
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="cephalosporin-blue">"Meningitis dose = 2g q12h"</strong> - double dose, double frequency for CNS penetration<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Once daily dosing:</strong> Long half-life allows single daily dose for most indications<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Penicillin allergy:</strong> 5-10% cross-reactivity - use with caution in Type I hypersensitivity<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Renal/hepatic dual excretion:</strong> No dose adjustment needed for renal failure alone<br>
        ‚Ä¢ <strong class="cephalosporin-blue">IM administration:</strong> Very painful - MUST use 1% lidocaine as diluent<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Calcium warning:</strong> Do not mix with calcium-containing solutions (precipitation risk)<br>
        ‚Ä¢ <strong class="cephalosporin-blue">C. diff risk:</strong> Lower than clindamycin, similar to other broad-spectrum antibiotics<br>
        ‚Ä¢ <strong class="cephalosporin-blue">Gonorrhoea resistance:</strong> Worldwide concern - always add azithromycin 1g PO
    </div>
</div>

<!-- CHAPTER 3: DRUG 2 - AMPICILLIN -->
<div class="page-break"></div>
<h2><span class="chapter-number">3</span> Core Drug 2: Ampicillin</h2>

<div class="drug-template">
    <h4>AMPICILLIN - AMINOPENICILLIN FOR GRAM-POSITIVE & SOME GRAM-NEGATIVE COVERAGE</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Aminopenicillin, beta-lactam antibiotic
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds penicillin-binding proteins ‚Üí inhibits bacterial cell wall synthesis<br>
        ‚Ä¢ Bactericidal (time-dependent killing)<br>
        ‚Ä¢ Broader spectrum than penicillin G: covers some gram-negatives (E. coli, Proteus, H. influenzae)<br>
        ‚Ä¢ Destroyed by beta-lactamases (most staph, many gram-negatives)<br>
        ‚Ä¢ Good CSF penetration when meninges inflamed (10-30% of serum levels)<br>
        ‚Ä¢ Primarily renal excretion (dose adjust in renal impairment)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Bacterial meningitis (with ceftriaxone/cefotaxime for Listeria coverage)<br>
        ‚Ä¢ Enterococcal infections (endocarditis, UTI - with aminoglycoside for synergy)<br>
        ‚Ä¢ Listeria monocytogenes infections (meningitis in neonates, elderly, immunocompromised)<br>
        ‚Ä¢ Community-acquired respiratory infections (with beta-lactamase inhibitor)<br>
        ‚Ä¢ Urinary tract infections (uncomplicated, but resistance common)<br>
        ‚Ä¢ Intra-abdominal infections (with metronidazole)<br>
        ‚Ä¢ Surgical prophylaxis (gastrointestinal, genitourinary procedures)<br>
        ‚Ä¢ Typhoid fever (though resistance increasing)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known severe hypersensitivity to ampicillin or penicillins<br>
        ‚Ä¢ Infectious mononucleosis (high rash incidence: 90-100%)<br>
        ‚Ä¢ Cytomegalovirus infection (increased rash risk)<br>
        ‚Ä¢ Acute lymphocytic leukemia (increased rash risk)<br>
        ‚Ä¢ Concurrent allopurinol use (increased rash risk)<br>
        ‚Ä¢ Severe renal impairment (CrCl <10 mL/min) without dose adjustment
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="penicillin-green">Moderate infections:</strong> 1-2 g IV q6h<br>
        ‚Ä¢ <strong class="penicillin-green">Severe infections:</strong> 2 g IV q4-6h<br>
        ‚Ä¢ <strong class="penicillin-green">Meningitis (Listeria coverage):</strong> 2 g IV q4h + gentamicin<br>
        ‚Ä¢ <strong class="penicillin-green">Enterococcal endocarditis:</strong> 2 g IV q4h + gentamicin 1 mg/kg q8h<br>
        ‚Ä¢ <strong class="penicillin-green">Urinary tract infections:</strong> 500 mg PO q6h or 1 g IV q6h<br>
        ‚Ä¢ <strong class="penicillin-green">Surgical prophylaxis:</strong> 2 g IV single dose 30-60 min before incision<br>
        ‚Ä¢ <strong class="penicillin-green">Max daily dose:</strong> 12 g (usually 8 g/day sufficient)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="penicillin-green">Neonates (0-7 days):</strong> 50 mg/kg IV q12h<br>
        ‚Ä¢ <strong class="penicillin-green">Neonates (8-28 days):</strong> 50 mg/kg IV q8h<br>
        ‚Ä¢ <strong class="penicillin-green">Infants/children:</strong> 100-200 mg/kg/day IV divided q6h (max 12 g/day)<br>
        ‚Ä¢ <strong class="penicillin-green">Meningitis:</strong> 200-300 mg/kg/day IV divided q4-6h (max 12 g/day)<br>
        ‚Ä¢ <strong class="penicillin-green">Oral:</strong> 50-100 mg/kg/day PO divided q6h (max 4 g/day)<br>
        ‚Ä¢ <strong class="penicillin-green">Renal adjustment:</strong> Required for CrCl <50 mL/min
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="penicillin-green">Routes:</strong> IV (preferred for severe infections), IM, PO<br>
        ‚Ä¢ <strong class="penicillin-green">Preparation:</strong> 250 mg, 500 mg, 1 g, 2 g vials (powder)<br>
        ‚Ä¢ <strong class="penicillin-green">IV reconstitution:</strong> Add 10 mL sterile water per 1 g = 100 mg/mL<br>
        ‚Ä¢ <strong class="penicillin-green">IV infusion:</strong> Further dilute in 50-100 mL NS or D5W, infuse over 30 min<br>
        ‚Ä¢ <strong class="penicillin-green">IM:</strong> Deep IM injection, rotate sites (painful)<br>
        ‚Ä¢ <strong class="penicillin-green">Compatibility:</strong> NOT with aminoglycosides (inactivates them), separate lines
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Rash (5-10%, usually maculopapular, non-allergic)<br>
        ‚Ä¢ Diarrhea (oral more than IV)<br>
        ‚Ä¢ Nausea, vomiting (especially oral)<br>
        ‚Ä¢ Injection site reactions<br>
        ‚Ä¢ Vaginal candidiasis (disturbance of normal flora)<br>
        ‚Ä¢ Elevated LFTs (transient)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Anaphylaxis (0.01-0.05%)<br>
        ‚Ä¢ Ampicillin rash (90-100% in EBV/CMV infections - non-allergic)<br>
        ‚Ä¢ Clostridioides difficile infection<br>
        ‚Ä¢ Pseudomembranous colitis<br>
        ‚Ä¢ Hemolytic anemia (immune-mediated)<br>
        ‚Ä¢ Interstitial nephritis (rare)<br>
        ‚Ä¢ Seizures (high doses, renal impairment)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="penicillin-green">Aminoglycosides:</strong> Physically incompatible (inactivates aminoglycosides)<br>
        ‚Ä¢ <strong class="penicillin-green">Allopurinol:</strong> Increased rash incidence (avoid combination)<br>
        ‚Ä¢ <strong class="penicillin-green">Methotrexate:</strong> Increased methotrexate toxicity (reduced renal clearance)<br>
        ‚Ä¢ <strong class="penicillin-green">Warfarin:</strong> Increased INR (suppresses vitamin K-producing gut flora)<br>
        ‚Ä¢ <strong class="penicillin-green">Oral contraceptives:</strong> Reduced efficacy (use backup contraception)<br>
        ‚Ä¢ <strong class="penicillin-green">Probenecid:</strong> Increases ampicillin levels (sometimes used intentionally)
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="penicillin-green">"Listeria coverage":</strong> Must add ampicillin to meningitis regimen if >50 years, immunocompromised, or neonate<br>
        ‚Ä¢ <strong class="penicillin-green">Ampicillin rash:</strong> 90-100% in EBV mononucleosis - NOT allergic, but often mistaken for allergy<br>
        ‚Ä¢ <strong class="penicillin-green">Enterococcus coverage:</strong> Only penicillin/ampicillin reliably cover enterococci (not cephalosporins)<br>
        ‚Ä¢ <strong class="penicillin-green">Beta-lactamase vulnerable:</strong> Destroyed by staph beta-lactamase - use flucloxacillin for staph<br>
        ‚Ä¢ <strong class="penicillin-green">Synergy with aminoglycosides:</strong> For enterococcal endocarditis - bactericidal combination<br>
        ‚Ä¢ <strong class="penicillin-green">Renal adjustment:</strong> Essential - ampicillin accumulates in renal failure<br>
        ‚Ä¢ <strong class="penicillin-green">CSF penetration:</strong> Good only with inflamed meninges (10-30% of serum levels)<br>
        ‚Ä¢ <strong class="penicillin-green">Oral absorption:</strong> Only 40% oral bioavailability - IV preferred for serious infections
    </div>
</div>

<!-- CHAPTER 4: DRUG 3 - GENTAMICIN -->
<div class="page-break"></div>
<h2><span class="chapter-number">4</span> Core Drug 3: Gentamicin</h2>

<div class="drug-template">
    <h4>GENTAMICIN - CONCENTRATION-DEPENDENT AMINOGLYCOSIDE</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Aminoglycoside antibiotic
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds 30S ribosomal subunit ‚Üí inhibits bacterial protein synthesis<br>
        ‚Ä¢ Bactericidal (concentration-dependent killing)<br>
        ‚Ä¢ Post-antibiotic effect (PAE) - continues killing after levels drop below MIC<br>
        ‚Ä¢ Synergistic with beta-lactams (penicillins/cephalosporins) for gram-positives<br>
        ‚Ä¢ Poor CSF penetration (even with inflamed meninges)<br>
        ‚Ä¢ Renal excretion exclusively ‚Üí accumulates in renal impairment
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Gram-negative sepsis (Pseudomonas, E. coli, Klebsiella, Enterobacter)<br>
        ‚Ä¢ Febrile neutropenia (with anti-pseudomonal beta-lactam)<br>
        ‚Ä¢ Synergy for gram-positive infections (enterococcal endocarditis with ampicillin)<br>
        ‚Ä¢ Complicated urinary tract infections (pyelonephritis)<br>
        ‚Ä¢ Intra-abdominal infections (with metronidazole/anaerobic coverage)<br>
        ‚Ä¢ Neonatal sepsis (with ampicillin)<br>
        ‚Ä¢ Osteomyelitis/septic arthritis (with anti-staphylococcal agent)<br>
        ‚Ä¢ Surgical prophylaxis (colorectal, some urological procedures)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to gentamicin or aminoglycosides<br>
        ‚Ä¢ Myasthenia gravis (exacerbates neuromuscular blockade)<br>
        ‚Ä¢ Severe renal impairment (CrCl <30 mL/min) without dose adjustment<br>
        ‚Ä¢ Concurrent use of other nephrotoxic/ototoxic drugs (if avoidable)<br>
        ‚Ä¢ Pregnancy (relative - risk of fetal ototoxicity, Category D)<br>
        ‚Ä¢ Pre-existing hearing loss/vestibular dysfunction
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="aminoglycoside-red">Once daily dosing (ODD):</strong> 5-7 mg/kg IV once daily (preferred)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Traditional dosing:</strong> 1.5-2 mg/kg IV q8h (less preferred now)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Synergy dosing (endocarditis):</strong> 1 mg/kg IV q8h with ampicillin<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Pneumonia (with pseudomonas risk):</strong> 7 mg/kg IV once daily<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Urinary tract infections:</strong> 5 mg/kg IV once daily (lower dose sufficient)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Surgical prophylaxis:</strong> 5 mg/kg IV single dose 30-60 min before incision<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Therapeutic drug monitoring (TDM):</strong> Essential for >3 days therapy
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="aminoglycoside-red">Neonates (0-7 days, <2kg):</strong> 3 mg/kg IV q24h<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Neonates (0-7 days, >2kg):</strong> 4 mg/kg IV q24h<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Neonates (>7 days):</strong> 5 mg/kg IV q24h<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Infants/children:</strong> 7.5 mg/kg IV once daily (or 2.5 mg/kg q8h)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Cystic fibrosis:</strong> Higher doses often needed (10-12 mg/kg/day)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Therapeutic drug monitoring:</strong> CRUCIAL in pediatrics
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="aminoglycoside-red">Routes:</strong> IV (preferred), IM, topical, intraocular, intra-thecal<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Preparation:</strong> 10 mg/mL, 40 mg/mL vials<br>
        ‚Ä¢ <strong class="aminoglycoside-red">IV infusion:</strong> Dilute in 50-100 mL NS or D5W, infuse over 30-60 minutes<br>
        ‚Ä¢ <strong class="aminoglycoside-red">IM:</strong> Deep IM injection, rotate sites<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Compatibility:</strong> NOT with penicillins/cephalosporins (inactivates gentamicin)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Storage:</strong> Room temperature, protected from light
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Nephrotoxicity (5-25%, usually reversible)<br>
        ‚Ä¢ Ototoxicity (2-25%, often irreversible)<br>
        ‚Ä¢ Neuromuscular blockade (especially with rapid infusion)<br>
        ‚Ä¢ Nausea, vomiting<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Rash, pruritus
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Acute kidney injury (dose and duration dependent)<br>
        ‚Ä¢ Permanent hearing loss (high frequency first)<br>
        ‚Ä¢ Vestibular toxicity (vertigo, ataxia, nystagmus)<br>
        ‚Ä¢ Respiratory paralysis (with rapid IV push or in myasthenia gravis)<br>
        ‚Ä¢ Hypomagnesemia, hypokalemia, hypocalcemia<br>
        ‚Ä¢ Encephalopathy (in renal failure)<br>
        ‚Ä¢ Peripheral neuropathy (rare)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="aminoglycoside-red">Other nephrotoxic drugs:</strong> Additive toxicity (vancomycin, amphotericin, cisplatin)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Other ototoxic drugs:</strong> Additive toxicity (loop diuretics, cisplatin)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Neuromuscular blockers:</strong> Potentiation of paralysis (suxamethonium, vecuronium)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Penicillins/cephalosporins:</strong> Physically incompatible (inactivates gentamicin)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Cyclosporin/tacrolimus:</strong> Increased nephrotoxicity<br>
        ‚Ä¢ <strong class="aminoglycoside-red">IV contrast:</strong> Increased nephrotoxicity risk
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="aminoglycoside-red">"Once daily dosing (ODD) preferred":</strong> 5-7 mg/kg once daily - better efficacy, less toxicity<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Therapeutic drug monitoring (TDM):</strong> Check levels before 4th dose (trough <1 mg/L)<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Peak levels:</strong> Not needed for ODD, only for traditional q8h dosing<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Nephrotoxicity:</strong> Monitor creatinine daily, stop if >50% increase from baseline<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Ototoxicity:</strong> Often irreversible - ask about tinnitus, hearing loss, dizziness<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Duration limit:</strong> Usually ‚â§7-10 days to minimize toxicity<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Synergy dosing:</strong> Lower dose (1 mg/kg q8h) for enterococcal endocarditis with ampicillin<br>
        ‚Ä¢ <strong class="aminoglycoside-red">Do NOT mix with penicillins:</strong> Inactivates gentamicin - give at different times, different lines
    </div>
</div>

<!-- CHAPTER 5: DRUG 4 - PIPERACILLIN-TAZOBACTAM -->
<div class="page-break"></div>
<h2><span class="chapter-number">5</span> Core Drug 4: Piperacillin-Tazobactam</h2>

<div class="drug-template">
    <h4>PIPERACILLIN-TAZOBACTAM - BROAD-SPECTRUM ANTI-PSEUDOMONAL PENICILLIN + BETA-LACTAMASE INHIBITOR</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Extended-spectrum penicillin + beta-lactamase inhibitor
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ <strong>Piperacillin:</strong> Binds penicillin-binding proteins ‚Üí inhibits cell wall synthesis<br>
        ‚Ä¢ <strong>Tazobactam:</strong> Irreversibly inhibits beta-lactamases (especially TEM, SHV, some ESBLs)<br>
        ‚Ä¢ Synergistic combination extends spectrum to beta-lactamase producers<br>
        ‚Ä¢ Bactericidal (time-dependent killing)<br>
        ‚Ä¢ Anti-pseudomonal activity (piperacillin component)<br>
        ‚Ä¢ Anaerobic coverage (good for intra-abdominal infections)<br>
        ‚Ä¢ Renal excretion (both components) ‚Üí dose adjust in renal impairment
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Hospital-acquired pneumonia (including ventilator-associated)<br>
        ‚Ä¢ Complicated intra-abdominal infections<br>
        ‚Ä¢ Complicated urinary tract infections (including pyelonephritis)<br>
        ‚Ä¢ Febrile neutropenia (with/without additional anti-pseudomonal)<br>
        ‚Ä¢ Skin and soft tissue infections (complicated, diabetic foot)<br>
        ‚Ä¢ Septicemia of unknown source<br>
        ‚Ä¢ Pelvic inflammatory disease (hospitalized patients)<br>
        ‚Ä¢ Bone and joint infections (as part of combination therapy)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known severe hypersensitivity to piperacillin, tazobactam, or penicillins<br>
        ‚Ä¢ History of anaphylaxis to penicillins<br>
        ‚Ä¢ Severe renal impairment (CrCl <20 mL/min) without extended interval dosing<br>
        ‚Ä¢ Concurrent use of sodium salts in sodium-restricted patients (high sodium content)<br>
        ‚Ä¢ Infectious mononucleosis (increased rash risk with penicillins)<br>
        ‚Ä¢ Cystic fibrosis with frequent use (may select for resistant organisms)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="pip-tazo-purple">Standard dosing:</strong> 4.5 g (4g piperacillin + 0.5g tazobactam) IV q6-8h<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Extended infusion:</strong> 4.5 g IV over 4 hours q8h (better PK/PD for resistant organisms)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Pseudomonas infections:</strong> 4.5 g IV q6h or extended infusion<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Renal impairment (CrCl 20-40):</strong> 3.375 g IV q6h or 2.25 g IV q6-8h<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Renal impairment (CrCl <20):</strong> 2.25 g IV q8h or 4.5 g IV q12h<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Hemodialysis:</strong> 2.25 g IV q12h, give after dialysis<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Max daily dose:</strong> 18 g piperacillin component (usually 13.5-16 g)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="pip-tazo-purple">Children 2-9 months:</strong> 80 mg piperacillin/kg (with 10 mg tazobactam/kg) IV q8h<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Children ‚â•9 months to 12 years:</strong> 100 mg piperacillin/kg (with 12.5 mg tazobactam/kg) IV q8h<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Children >12 years or >40 kg:</strong> Adult dosing<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Appendicitis/peritonitis:</strong> 100 mg piperacillin/kg (with 12.5 mg tazobactam/kg) IV q8h<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Neonates:</strong> Limited data, consult specialist<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Renal adjustment:</strong> Required for pediatric patients with renal impairment
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="pip-tazo-purple">Routes:</strong> IV only (not for IM use)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Preparation:</strong> 2.25 g, 3.375 g, 4.5 g vials (powder)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Reconstitution:</strong> Add diluent (sterile water/NS) per manufacturer instructions<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Standard infusion:</strong> Dilute in 50-100 mL, infuse over 30 minutes<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Extended infusion:</strong> Dilute in 50-250 mL, infuse over 4 hours<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Compatibility:</strong> NOT with aminoglycosides in same line (inactivates them)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Diarrhea (7-11%)<br>
        ‚Ä¢ Headache (7%)<br>
        ‚Ä¢ Insomnia (7%)<br>
        ‚Ä¢ Constipation (7%)<br>
        ‚Ä¢ Nausea, vomiting (4-6%)<br>
        ‚Ä¢ Rash, pruritus (3-4%)<br>
        ‚Ä¢ Injection site reactions (2%)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Anaphylaxis (rare)<br>
        ‚Ä¢ Clostridioides difficile infection (antibiotic-associated colitis)<br>
        ‚Ä¢ Leukopenia, neutropenia (especially with prolonged use)<br>
        ‚Ä¢ Hepatitis, elevated LFTs (1-2%)<br>
        ‚Ä¢ Seizures (high doses, renal impairment)<br>
        ‚Ä¢ Interstitial nephritis (rare)<br>
        ‚Ä¢ Hypokalemia (piperacillin has anti-mineralocorticoid effect)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="pip-tazo-purple">Aminoglycosides:</strong> Synergistic but physically incompatible (separate lines)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Vecuronium:</strong> Prolongs neuromuscular blockade<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Methotrexate:</strong> Increases methotrexate toxicity (reduced renal clearance)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Oral contraceptives:</strong> Reduced efficacy (use backup)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Probenecid:</strong> Increases piperacillin levels (rarely used together)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Heparin:</strong> May increase bleeding risk (affects platelet function)
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="pip-tazo-purple">"Workhorse of empiric sepsis therapy":</strong> Broad coverage for most ICU pathogens<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Extended infusion:</strong> 4.5g over 4h q8h ‚Üí better time above MIC for resistant organisms<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Pseudomonas coverage:</strong> One of few penicillins with reliable anti-pseudomonal activity<br>
        ‚Ä¢ <strong class="pip-tazo-purple">ESBL coverage:</strong> Tazobactam inhibits some (not all) ESBLs - carbapenems preferred for known ESBL<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Sodium load:</strong> 4.5g contains ~9 mmol sodium - consider in heart failure, renal failure<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Renal adjustment:</strong> CRITICAL - accumulates in renal failure (seizure risk)<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Not for MRSA:</strong> Does NOT cover MRSA - add vancomycin/linezolid if MRSA suspected<br>
        ‚Ä¢ <strong class="pip-tazo-purple">Penicillin allergy:</strong> Avoid if Type I (anaphylaxis) - carbapenem or aztreonam alternative
    </div>
</div>

<!-- CHAPTER 6: DRUG 5 - VANCOMYCIN -->
<div class="page-break"></div>
<h2><span class="chapter-number">6</span> Core Drug 5: Vancomycin (Emergency Basics)</h2>

<div class="drug-template">
    <h4>VANCOMYCIN - GLYCOPEPTIDE FOR MRSA & SERIOUS GRAM-POSITIVE INFECTIONS</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Glycopeptide antibiotic
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds D-alanyl-D-alanine portion of cell wall precursors ‚Üí inhibits cell wall synthesis<br>
        ‚Ä¢ Bactericidal against most gram-positives (bacteriostatic against enterococci)<br>
        ‚Ä¢ Time-dependent killing (AUC/MIC ratio predicts efficacy)<br>
        ‚Ä¢ Poor CSF penetration (achieves therapeutic levels only with inflamed meninges)<br>
        ‚Ä¢ Renal excretion exclusively ‚Üí accumulates in renal impairment<br>
        ‚Ä¢ Not absorbed orally (except for C. difficile colitis treatment)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Methicillin-resistant Staphylococcus aureus (MRSA) infections<br>
        ‚Ä¢ Penicillin-resistant Streptococcus pneumoniae infections<br>
        ‚Ä¢ Serious gram-positive infections in penicillin-allergic patients<br>
        ‚Ä¢ Infective endocarditis (with gentamicin for synergy in some cases)<br>
        ‚Ä¢ Meningitis (with ceftriaxone for empiric coverage of resistant pneumococcus)<br>
        ‚Ä¢ Clostridioides difficile colitis (oral formulation only)<br>
        ‚Ä¢ Surgical prophylaxis (in penicillin-allergic patients, procedures with MRSA risk)<br>
        ‚Ä¢ Empirical therapy for severe sepsis of unknown source
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known severe hypersensitivity to vancomycin<br>
        ‚Ä¢ Concurrent use with other ototoxic/nephrotoxic drugs (if alternatives exist)<br>
        ‚Ä¢ Severe renal impairment without dose adjustment<br>
        ‚Ä¢ Avoid in pregnancy unless absolutely necessary (Category C)<br>
        ‚Ä¢ Not for trivial infections or as first-line for susceptible organisms<br>
        ‚Ä¢ Avoid in patients with hearing loss (ototoxicity risk)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="vancomycin-orange">Loading dose:</strong> 25-30 mg/kg IV (actual body weight, max 2-3g)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Maintenance:</strong> 15-20 mg/kg IV q8-12h (based on renal function)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Meningitis/endocarditis:</strong> Higher doses to achieve trough 15-20 mg/L<br>
        ‚Ä¢ <strong class="vancomycin-orange">Skin/soft tissue:</strong> Lower trough target 10-15 mg/L usually sufficient<br>
        ‚Ä¢ <strong class="vancomycin-orange">Oral for C. diff:</strong> 125 mg PO q6h for 10 days (IV vancomycin NOT effective for C. diff)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Therapeutic drug monitoring (TDM):</strong> ESSENTIAL - check trough before 4th dose
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="vancomycin-orange">Neonates (0-7 days):</strong> 15 mg/kg IV q24h<br>
        ‚Ä¢ <strong class="vancomycin-orange">Neonates (8-28 days):</strong> 15 mg/kg IV q12h<br>
        ‚Ä¢ <strong class="vancomycin-orange">Infants/children:</strong> 15 mg/kg IV q6-8h (adjust for renal function)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Meningitis:</strong> 60 mg/kg/day IV divided q6h (higher doses needed)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Oral for C. diff:</strong> 10 mg/kg PO q6h (max 125 mg/dose)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Therapeutic drug monitoring:</strong> CRITICAL in pediatrics
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="vancomycin-orange">Routes:</strong> IV (for systemic infections), PO (for C. diff only)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Preparation:</strong> 500 mg, 1 g, 5 g, 10 g vials (powder)<br>
        ‚Ä¢ <strong class="vancomycin-orange">IV reconstitution:</strong> Add 10 mL sterile water per 500 mg = 50 mg/mL<br>
        ‚Ä¢ <strong class="vancomycin-orange">IV infusion:</strong> Further dilute to ‚â§5 mg/mL (e.g., 1g in 200 mL), infuse over ‚â•60 min<br>
        ‚Ä¢ <strong class="vancomycin-orange">SLOW infusion:</strong> Minimum 60 minutes to avoid Red Man Syndrome<br>
        ‚Ä¢ <strong class="vancomycin-orange">Compatibility:</strong> NOT with aminoglycosides, beta-lactams, heparin in same line
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Red Man Syndrome (flushing, pruritus, rash - infusion rate related)<br>
        ‚Ä¢ Nephrotoxicity (5-25%, usually reversible)<br>
        ‚Ä¢ Ototoxicity (rare, usually with high troughs or concurrent ototoxins)<br>
        ‚Ä¢ Phlebitis at injection site<br>
        ‚Ä¢ Nausea, chills, fever<br>
        ‚Ä¢ Eosinophilia, rash
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Acute kidney injury (dose and trough related)<br>
        ‚Ä¢ Permanent hearing loss (associated with troughs >20 mg/L)<br>
        ‚Ä¢ Neutropenia (with prolonged therapy, usually reversible)<br>
        ‚Ä¢ Thrombocytopenia (rare)<br>
        ‚Ä¢ Stevens-Johnson syndrome/toxic epidermal necrolysis (rare)<br>
        ‚Ä¢ DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)<br>
        ‚Ä¢ Cardiac arrest (with rapid infusion - "Vancomycin infusion syndrome")
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="vancomycin-orange">Aminoglycosides:</strong> Additive nephrotoxicity and ototoxicity<br>
        ‚Ä¢ <strong class="vancomycin-orange">Loop diuretics (furosemide):</strong> Additive ototoxicity<br>
        ‚Ä¢ <strong class="vancomycin-orange">Other nephrotoxins:</strong> Amphotericin, cisplatin, cyclosporin<br>
        ‚Ä¢ <strong class="vancomycin-orange">Anesthetic agents:</strong> May enhance neuromuscular blockade<br>
        ‚Ä¢ <strong class="vancomycin-orange">Warfarin:</strong> May increase INR (reported cases)<br>
        ‚Ä¢ <strong class="vancomycin-orange">IV contrast:</strong> Additive nephrotoxicity risk
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="vancomycin-orange">"Slow infusion ‚â•60 minutes":</strong> Prevents Red Man Syndrome<br>
        ‚Ä¢ <strong class="vancomycin-orange">Therapeutic drug monitoring:</strong> Trough level before 4th dose (target 10-20 mg/L)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Loading dose:</strong> 25-30 mg/kg for serious infections (achieves therapeutic levels faster)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Red Man Syndrome:</strong> Not allergic - slow infusion, pre-treat with antihistamine if recurrent<br>
        ‚Ä¢ <strong class="vancomycin-orange">MRSA pneumonia:</strong> Trough 15-20 mg/L (higher than for other indications)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Oral vancomycin:</strong> NOT absorbed - only for C. diff colitis (IV doesn't work for C. diff)<br>
        ‚Ä¢ <strong class="vancomycin-orange">Penetration:</strong> Poor into CSF, lung, bone - may need higher doses for these sites<br>
        ‚Ä¢ <strong class="vancomycin-orange">Duration:</strong> Usually 7-14 days, longer for endocarditis, osteomyelitis (6 weeks)
    </div>
</div>

<!-- CHAPTER 7: DRUG 6 - ARTESUNATE -->
<div class="page-breax"></div>
<h2><span class="chapter-number">7</span> Core Drug 6: Artesunate</h2>

<div class="drug-template">
    <h4>ARTESUNATE - FIRST-LINE FOR SEVERE MALARIA</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Artemisinin derivative, antimalarial
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Active metabolite (dihydroartemisinin) generates free radicals ‚Üí damages parasite membranes<br>
        ‚Ä¢ Rapidly reduces parasite biomass (most rapid of all antimalarials)<br>
        ‚Ä¢ Acts on all stages of parasite life cycle (including early gametocytes)<br>
        ‚Ä¢ Short half-life (45 minutes) but active metabolites last longer<br>
        ‚Ä¢ Synergistic with longer-acting partner drugs (prevents recrudescence)<br>
        ‚Ä¢ No cross-resistance with other antimalarial classes (usually)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Severe malaria (Plasmodium falciparum, knowlesi, vivax with severe features)<br>
        ‚Ä¢ Uncomplicated malaria (as part of Artemisinin Combination Therapy - ACT)<br>
        ‚Ä¢ First-line for all malaria in artemisinin-sensitive regions<br>
        ‚Ä¢ Malaria in pregnancy (2nd/3rd trimester - 1st trimester quinine preferred)<br>
        ‚Ä¢ Cerebral malaria (superior to quinine)<br>
        ‚Ä¢ Imported malaria in non-endemic countries<br>
        ‚Ä¢ Pre-referral treatment in remote settings (rectal formulation)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to artemisinins<br>
        ‚Ä¢ First trimester of pregnancy (relative - quinine preferred)<br>
        ‚Ä¢ Concurrent use with strong CYP2A6 inducers (may reduce efficacy)<br>
        ‚Ä¢ History of prolonged QT interval (less risk than other antimalarials)<br>
        ‚Ä¢ Breastfeeding (limited data, but benefits usually outweigh risks in severe malaria)<br>
        ‚Ä¢ Neonates (limited data, use under specialist guidance)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="antimalarial-teal">Severe malaria (IV):</strong> 2.4 mg/kg at 0, 12, 24h, then once daily until oral possible<br>
        ‚Ä¢ <strong class="antimalarial-teal">Uncomplicated malaria (oral):</strong> 4 mg/kg daily √ó 3 days + partner drug (ACT)<br>
        ‚Ä¢ <strong class="antimalarial-teal">IM alternative:</strong> 2.4 mg/kg IM, then at 12h and 24h, then daily<br>
        ‚Ä¢ <strong class="antimalarial-teal">Switch to oral:</strong> When patient can tolerate, complete with 3-day ACT course<br>
        ‚Ä¢ <strong class="antimalarial-teal">Rectal (pre-referral):</strong> 10 mg/kg single dose (adults/children same)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Max single dose:</strong> 150 mg (vial size limitation)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="antimalarial-teal">Severe malaria (IV):</strong> 2.4 mg/kg at 0, 12, 24h, then once daily<br>
        ‚Ä¢ <strong class="antimalarial-teal">Weight-based vials:</strong> Use appropriate vial size (60mg if 20-25kg, etc.)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Neonates/infants:</strong> Same mg/kg dosing (limited data in <5kg)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Oral ACT:</strong> Weight-based tablets available (20/120mg, 40/240mg artesunate/sulfadoxine-pyrimethamine)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Rectal:</strong> 10 mg/kg single dose for pre-referral
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="antimalarial-teal">Routes:</strong> IV (preferred), IM, rectal, oral<br>
        ‚Ä¢ <strong class="antimalarial-teal">Preparation:</strong> 60 mg powder vial with 1 mL 5% sodium bicarbonate ampoule<br>
        ‚Ä¢ <strong class="antimalarial-teal">IV reconstitution:</strong> Add sodium bicarbonate to powder, swirl until clear (~1 min)<br>
        ‚Ä¢ <strong class="antimalarial-teal">IV dilution:</strong> Add to 5 mL 5% dextrose (final ~10 mg/mL), give immediately<br>
        ‚Ä¢ <strong class="antimalarial-teal">IV administration:</strong> Bolus over 1-2 minutes (NOT infusion)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Stability:</strong> Use within 1 hour of reconstitution (unstable in solution)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Transient reticulocytopenia (days 7-14, recovers by day 21)<br>
        ‚Ä¢ Nausea, vomiting, diarrhea<br>
        ‚Ä¢ Dizziness, headache<br>
        ‚Ä¢ Transient first-degree heart block (rare, resolves spontaneously)<br>
        ‚Ä¢ Dark urine (not haemoglobinuria)<br>
        ‚Ä¢ Injection site pain (IM route)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Delayed haemolytic anaemia (7-21 days post-treatment, "post-artesunate delayed haemolysis")<br>
        ‚Ä¢ Allergic reactions (rare)<br>
        ‚Ä¢ Neutropenia (rare)<br>
        ‚Ä¢ Hepatotoxicity (rare)<br>
        ‚Ä¢ Cardiovascular effects (QT prolongation less than quinine)<br>
        ‚Ä¢ Neurotoxicity (in animal studies, not clearly demonstrated in humans)<br>
        ‚Ä¢ Teratogenicity (theoretical, avoid in 1st trimester)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="antimalarial-teal">Other antimalarials:</strong> Synergistic (used in combination therapy)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Enzyme inducers:</strong> Rifampicin, carbamazepine may reduce levels<br>
        ‚Ä¢ <strong class="antimalarial-teal">Antiretroviral drugs:</strong> Complex interactions, consult specialist<br>
        ‚Ä¢ <strong class="antimalarial-teal">Warfarin:</strong> Potential interaction (monitor INR)<br>
        ‚Ä¢ <strong class="antimalarial-teal">CYP2A6 inhibitors:</strong> May increase artesunate levels<br>
        ‚Ä¢ <strong class="antimalarial-teal">Mefloquine:</strong> Increased risk of neuropsychiatric effects
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="antimalarial-teal">"First-line for severe malaria":</strong> 35% mortality reduction compared to quinine<br>
        ‚Ä¢ <strong class="antimalarial-teal">Dosing regimen:</strong> 2.4 mg/kg at 0, 12, 24h, then daily (NOT weight bands, exact kg)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Reconstitution:</strong> MUST use sodium bicarbonate provided - won't dissolve otherwise<br>
        ‚Ä¢ <strong class="antimalarial-teal">IV bolus, not infusion:</strong> Give over 1-2 minutes (stability issues)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Complete treatment:</strong> Switch to oral ACT (artemether-lumefantrine, etc.) when able<br>
        ‚Ä¢ <strong class="antimalarial-teal">Delayed haemolysis:</strong> Monitor Hb days 7, 14, 21 - may need transfusion<br>
        ‚Ä¢ <strong class="antimalarial-teal">Pregnancy 1st trimester:</strong> Quinine + clindamycin preferred (artesunate if benefits > risks)<br>
        ‚Ä¢ <strong class="antimalarial-teal">Artemisinin resistance:</strong> Emerging in Southeast Asia - still effective elsewhere
    </div>
</div>

<div class="malaria-box">
    <strong>ü¶ü SEVERE MALARIA CRITERIA (WHO):</strong><br>
    ‚Ä¢ Impaired consciousness/coma (cerebral malaria)<br>
    ‚Ä¢ Prostration (unable to sit/stand)<br>
    ‚Ä¢ Multiple convulsions (>2 in 24h)<br>
    ‚Ä¢ Acidosis (pH <7.35, bicarbonate <15 mmol/L)<br>
    ‚Ä¢ Severe anaemia (Hb <7 g/dL or Hct <20%)<br>
    ‚Ä¢ Renal impairment (creatinine >265 Œºmol/L)<br>
    ‚Ä¢ Jaundice (bilirubin >50 Œºmol/L)<br>
    ‚Ä¢ Pulmonary edema/ARDS<br>
    ‚Ä¢ Significant bleeding/DIC<br>
    ‚Ä¢ Shock (SBP <80 mmHg with cool extremities)<br>
    ‚Ä¢ Parasitemia >10% or >100,000/ŒºL in low transmission areas
</div>

<!-- CHAPTER 8: EMPIRIC ANTIBIOTIC GUIDELINES -->
<div class="page-break"></div>
<h2><span class="chapter-number">8</span> Empiric Antibiotic Guidelines</h2>

<h3>8.1 Common Infection Syndromes & Empiric Therapy</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Infection Syndrome</th>
            <th>Likely Pathogens</th>
            <th>First-line Empiric Therapy</th>
            <th>Penicillin Allergy Alternative</th>
            <th>Comments</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Community-acquired pneumonia</strong></td>
            <td>S. pneumoniae, H. influenzae, atypical (Mycoplasma, Legionella)</td>
            <td>Amoxicillin 1g IV q6h + Doxycycline OR Ceftriaxone 2g IV daily + Azithromycin</td>
            <td>Moxifloxacin 400mg IV daily OR Doxycycline + Azithromycin</td>
            <td>Add MRSA coverage if recent hospitalization, antibiotics, cavitation</td>
        </tr>
        <tr>
            <td><strong>Meningitis (community)</strong></td>
            <td>S. pneumoniae, N. meningitidis, Listeria (if risk factors)</td>
            <td>Ceftriaxone 2g IV q12h + Vancomycin 15-20 mg/kg IV q8-12h + Dexamethasone</td>
            <td>Chloramphenicol + Vancomycin + Dexamethasone (consult ID)</td>
            <td>Add Ampicillin 2g IV q4h if >50y, immunocompromised, neonate (Listeria)</td>
        </tr>
        <tr>
            <td><strong>Pyelonephritis/UTI sepsis</strong></td>
            <td>E. coli, Klebsiella, Proteus, Enterococcus</td>
            <td>Ceftriaxone 2g IV daily OR Gentamicin 5 mg/kg IV daily</td>
            <td>Ciprofloxacin 400mg IV q12h (if sensitive) OR Aztreonam 2g IV q8h</td>
            <td>Consider ESBL risk if recent antibiotics, healthcare exposure, travel</td>
        </tr>
        <tr>
            <td><strong>Intra-abdominal infection</strong></td>
            <td>Coliforms, anaerobes (Bacteroides), Enterococcus</td>
            <td>Piperacillin-tazobactam 4.5g IV q8h OR Ertapenem 1g IV daily</td>
            <td>Metronidazole 500mg IV q8h + Ciprofloxacin 400mg IV q12h</td>
            <td>Source control (drainage, surgery) as important as antibiotics</td>
        </tr>
        <tr>
            <td><strong>Skin/soft tissue (necrotizing)</strong></td>
            <td>Mixed: Strep, Staph, anaerobes, gram-negatives</td>
            <td>Piperacillin-tazobactam 4.5g IV q6h + Clindamycin 600mg IV q8h</td>
            <td>Vancomycin 15-20 mg/kg IV q8-12h + Metronidazole + Aztreonam</td>
            <td>Clindamycin inhibits toxin production (toxic shock syndrome)</td>
        </tr>
        <tr>
            <td><strong>Febrile neutropenia</strong></td>
            <td>Gram-negatives (Pseudomonas), gram-positives, fungi if prolonged</td>
            <td>Piperacillin-tazobactam 4.5g IV q6h OR Meropenem 1g IV q8h</td>
            <td>Cefepime 2g IV q8h + Vancomycin (if line infection suspected)</td>
            <td>Add antifungal if fever persists >4-7 days on broad-spectrum antibiotics</td>
        </tr>
    </tbody>
</table>

<h3>8.2 Antibiotic Pharmacokinetics/Pharmacodynamics (PK/PD)</h3>

<div class="antimicrobial-grid">
    <strong>üß™ ANTIBIOTIC PK/PD CLASSES:</strong><br>
    <br>
    <strong>1. TIME-DEPENDENT KILLING (Œ≤-lactams, vancomycin):</strong><br>
    ‚Ä¢ Efficacy determined by time above MIC (%T>MIC)<br>
    ‚Ä¢ Goal: Maintain levels above MIC for 40-70% of dosing interval<br>
    ‚Ä¢ Dosing strategy: Frequent dosing or continuous infusion<br>
    ‚Ä¢ Examples: Penicillins, cephalosporins, carbapenems, vancomycin<br>
    <br>
    <strong>2. CONCENTRATION-DEPENDENT KILLING (Aminoglycosides, fluoroquinolones):</strong><br>
    ‚Ä¢ Efficacy determined by peak concentration to MIC ratio (Cmax/MIC)<br>
    ‚Ä¢ Have post-antibiotic effect (PAE)<br>
    ‚Ä¢ Dosing strategy: High dose, less frequent (once daily for aminoglycosides)<br>
    ‚Ä¢ Examples: Gentamicin, tobramycin, ciprofloxacin, levofloxacin<br>
    <br>
    <strong>3. AUC-DEPENDENT KILLING (Vancomycin, azithromycin, tetracyclines):</strong><br>
    ‚Ä¢ Efficacy determined by area under curve to MIC ratio (AUC/MIC)<br>
    ‚Ä¢ Dosing strategy: Optimize total daily dose (can be divided or once daily)<br>
    ‚Ä¢ Examples: Vancomycin, linezolid, tigecycline, azithromycin
</div>

<!-- CHAPTER 9: ANTIMICROBIAL STEWARDSHIP IN EMERGENCIES -->
<div class="page-break"></div>
<h2><span class="chapter-number">9</span> Antimicrobial Stewardship in Emergencies</h2>

<div class="sepsis-protocol">
    <h3>9.1 The 5 D's of Antimicrobial Stewardship</h3>
    
    <strong>1. DIAGNOSIS:</strong> Accurate diagnosis before antibiotics if possible<br>
    ‚Ä¢ Cultures before antibiotics (blood x2, urine, sputum, CSF as indicated)<br>
    ‚Ä¢ Imaging to identify source<br>
    ‚Ä¢ Biomarkers (procalcitonin to guide antibiotic duration)<br>
    <br>
    <strong>2. DRUG:</strong> Right drug for the likely pathogen<br>
    ‚Ä¢ Local antibiogram knowledge<br>
    ‚Ä¢ Narrowest spectrum that covers likely pathogens<br>
    ‚Ä¢ Consider resistance risk factors (recent antibiotics, healthcare exposure, travel)<br>
    <br>
    <strong>3. DOSE:</strong> Right dose for the site and patient<br>
    ‚Ä¢ Weight-based dosing for obese, pediatric patients<br>
    ‚Ä¢ Renal/hepatic adjustment<br>
    ‚Ä¢ Loading doses for severe infections (vancomycin, aminoglycosides)<br>
    <br>
    <strong>4. DURATION:</strong> Right duration - not too short, not too long<br>
    ‚Ä¢ CAP: 5-7 days (if good response)<br>
    ‚Ä¢ UTI: 7 days (pyelonephritis), 3 days (cystitis)<br>
    ‚Ä¢ Intra-abdominal: 4-7 days if source controlled<br>
    ‚Ä¢ Stop antibiotics if non-infectious cause identified<br>
    <br>
    <strong>5. DE-ESCALATION:</strong> Narrow spectrum when culture results available<br>
    ‚Ä¢ Day 3: Review cultures, narrow spectrum if possible<br>
    ‚Ä¢ Switch IV to oral when appropriate (clinical improvement, tolerating oral)<br>
    ‚Ä¢ Stop antibiotics if cultures negative and alternative diagnosis
</div>

<h3>9.2 Antibiotic Allergy Management</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Allergy Type</th>
            <th>Reaction Description</th>
            <th>Risk of Cross-reactivity</th>
            <th>Safe Alternatives</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Type I (Immediate)</strong><br>Anaphylaxis, urticaria, angioedema</td>
            <td>Occurs within 1 hour, IgE-mediated</td>
            <td>Penicillins ‚Üí Cephalosporins: 5-10%<br>Penicillins ‚Üí Carbapenems: <1%<br>Penicillins ‚Üí Aztreonam: 0%</td>
            <td>Aztreonam (gram-negatives)<br>Vancomycin (gram-positives)<br>Fluoroquinolones, aminoglycosides</td>
        </tr>
        <tr>
            <td><strong>Type IV (Delayed)</strong><br>Maculopapular rash, DRESS, SJS</td>
            <td>Occurs days to weeks, T-cell mediated</td>
            <td>Cross-reactivity less predictable<br>Often drug-specific, not class-wide</td>
            <td>Different class antibiotics<br>Consider allergy testing/desensitization if needed</td>
        </tr>
        <tr>
            <td><strong>Non-allergic "Allergy"</strong><br>GI upset, headache, vaginitis</td>
            <td>Side effects, not immunologic</td>
            <td>None (not true allergy)</td>
            <td>Usually safe to use same class<br>May tolerate with pre-medication</td>
        </tr>
        <tr>
            <td><strong>Ampicillin/Amoxicillin rash</strong><br>with EBV/CMV infection</td>
            <td>90-100% get rash, NOT allergic</td>
            <td>Not applicable (not allergy)</td>
            <td>Safe to use penicillins after infection resolved</td>
        </tr>
    </tbody>
</table>

<!-- APPENDIX: QUICK REFERENCE GUIDES -->
<div class="page-break"></div>
<h2>Appendix: Quick Reference Guides</h2>

<h3>Emergency Antimicrobial Dosing Quick Guide</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Antibiotic</th>
            <th>Adult Dose</th>
            <th>Pediatric Dose</th>
            <th>Key Spectrum</th>
            <th>Special Considerations</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Ceftriaxone</strong></td>
            <td>1-2g IV daily (2g q12h meningitis)</td>
            <td>50-75 mg/kg IV daily (100 mg/kg load for meningitis)</td>
            <td>Gram-positives, gram-negatives (not Pseudomonas), some anaerobes</td>
            <td>Once daily, long half-life, avoid with calcium solutions</td>
        </tr>
        <tr>
            <td><strong>Ampicillin</strong></td>
            <td>1-2g IV q4-6h</td>
            <td>100-200 mg/kg/day IV divided q6h</td>
            <td>Gram-positives (including Enterococcus, Listeria), some gram-negatives</td>
            <td>Add to meningitis regimen if Listeria risk, EBV rash common</td>
        </tr>
        <tr>
            <td><strong>Gentamicin</strong></td>
            <td>5-7 mg/kg IV once daily</td>
            <td>7.5 mg/kg IV once daily</td>
            <td>Gram-negatives (including Pseudomonas), synergy for gram-positives</td>
            <td>Nephrotoxic/ototoxic, TDM required, once daily preferred</td>
        </tr>
        <tr>
            <td><strong>Piperacillin-Tazobactam</strong></td>
            <td>4.5g IV q6-8h</td>
            <td>100 mg/kg piperacillin component IV q8h</td>
            <td>Broad: gram-positives, gram-negatives (including Pseudomonas), anaerobes</td>
            <td>Empiric sepsis workhorse, extended infusion for resistant organisms</td>
        </tr>
        <tr>
            <td><strong>Vancomycin</strong></td>
            <td>15-20 mg/kg IV q8-12h (load 25-30 mg/kg)</td>
            <td>15 mg/kg IV q6-8h</td>
            <td>Gram-positives (including MRSA, resistant pneumococcus)</td>
            <td>TDM essential (trough 10-20 mg/L), infuse over ‚â•60 min</td>
        </tr>
        <tr>
            <td><strong>Artesunate</strong></td>
            <td>2.4 mg/kg at 0, 12, 24h then daily</td>
            <td>2.4 mg/kg same schedule</td>
            <td>Plasmodium falciparum, knowlesi, vivax</td>
            <td>First-line for severe malaria, IV bolus (not infusion), complete with ACT</td>
        </tr>
    </tbody>
</table>

<h3>Sepsis Time Targets</h3>

<div class="clinical-pearl">
    <strong>‚è±Ô∏è SEPSIS TIME TARGETS (SURVIVING SEPSIS CAMPAIGN):</strong><br>
    <br>
    <strong>WITHIN 1 HOUR:</strong><br>
    ‚Ä¢ Measure lactate, re-measure if >2 mmol/L<br>
    ‚Ä¢ Obtain blood cultures before antibiotics<br>
    ‚Ä¢ Administer broad-spectrum antibiotics<br>
    ‚Ä¢ Begin 30 mL/kg crystalloid for hypotension or lactate ‚â•4 mmol/L<br>
    <br>
    <strong>WITHIN 3 HOURS:</strong><br>
    ‚Ä¢ Complete initial bolus (30 mL/kg) if indicated<br>
    ‚Ä¢ Measure central venous pressure (CVP) if on vasopressors<br>
    ‚Ä¢ Measure central venous oxygen saturation (ScvO‚ÇÇ) if available<br>
    <br>
    <strong>WITHIN 6 HOURS:</strong><br>
    ‚Ä¢ Apply vasopressors for hypotension not responding to fluids<br>
    ‚Ä¢ Re-measure lactate if initial was elevated<br>
    ‚Ä¢ Achieve resuscitation targets: MAP ‚â•65 mmHg, urine output ‚â•0.5 mL/kg/hr<br>
    ‚Ä¢ Normalize lactate if elevated
</div>

<h3>Therapeutic Drug Monitoring (TDM) Guidelines</h3>
<ol>
    <li><strong>Vancomycin:</strong> Trough level before 4th dose
        <ul class="sub-list">
            <li>Target: 10-15 mg/L for most infections</li>
            <li>Target: 15-20 mg/L for pneumonia, meningitis, endocarditis</li>
            <li>Check weekly if stable renal function, more often if changing</li>
        </ul>
    </li>
    <li><strong>Gentamicin/Tobramycin (once daily):</strong> Trough before 4th dose
        <ul class="sub-list">
            <li>Target: <1 mg/L (to prevent accumulation)</li>
            <li>Peak levels not needed for once daily dosing</li>
            <li>Check every 3-4 days or with changing renal function</li>
        </ul>
    </li>
    <li><strong>Aminoglycosides (traditional dosing):</strong> Peak and trough
        <ul class="sub-list">
            <li>Peak (30 min post-dose): 5-10 mg/L</li>
            <li>Trough (<1 mg/L for q8h, <2 mg/L for q12h)</li>
        </ul>
    </li>
    <li><strong>Beta-lactams (selected cases):</strong> Trough levels
        <ul class="sub-list">
            <li>Consider for critically ill, burns, cystic fibrosis, renal replacement</li>
            <li>Target: 4-8x MIC for the suspected pathogen</li>
        </ul>
    </li>
</ol>

<div class="footer-note">
    <strong>¬© Emergency Medicine Education Team | Confidential Educational Material</strong><br>
    This document is for educational purposes only. Always follow local protocols and guidelines.<br>
    Medications and doses may vary by institution. Verify all information before clinical application.<br>
    Version 1.0 | Last updated: [Current Date] | Module 8 of 10
</div>

</body>
</html>